The invention provides a novel benzoxazepine compound of the general formula (I):
wherein R
1
and R
2
are as defined in the specification; or a stereoisomer, a geometric isomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or a polymorph thereof; a process for its preparation; and a pharmaceutical composition including an effective amount of the compound. The compounds are useful in the treatment of insulin resistance and clinical conditions associated therewith.
本发明提供了一种新的苯并
噁唑烷化合物,其通式为(I),其中R1和R2如规范中定义;或其立体异构体,几何异构体,药学上可接受的盐,药学上可接受的溶剂化物或其多晶形式;其制备方法;以及包括该化合物的有效量的药物组合物。该化合物在治疗
胰岛素抵抗和相关临床病症方面具有有用性。